Integrating PLCM strategy in Pharmaceutical Emerging Market
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 4
Abstract
All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in a way that the product is manifesting i.e. its mirror image with respect of sales. Ultimately increase of sustainable profit is the aim that every company aspires of the PLCM strategy. The understanding of a product‘s life cycle, can help a company to understand and realize when it is time to introduce and withdraw a product from a market, its position in the market compared to competitors, and the product‘s success or failure. This article details regarding Product Lifecycle Management in light of Pharmaceutical environment for the emerging markets (India, China, Russia, Brazil, and South Africa). Also an attempt has been made to compare PLCM of stated emerging countries with- highly regulated market (US).
Authors and Affiliations
Swagat Tripathy, Padala Narasimha Murthy, Bibhu Prasad Patra
Keywords
Related Articles
- EP ID EP426993
- DOI 10.22270/ijdra.v6i4.280
- Views 102
- Downloads 0
RISK ANALYSIS EVALUATION OF PIROXICAM 20MG CAPSULES MANUFACTURE PROCESS BY FMEA TECHNIQUE
This paper presents an application of FMEA (Failure Mode and Effects Analysis) on the manufacturing process of Piroxicam 20mg capsules, with the objective of identifying possible failures and creates subsidies for improv...
CONDUCIVE ENVIROMENT FOR FOSTERING INDIA SPECIFIC INNOVATION: NEW MEDICAL DEVICE RULES 2017
The medical technology sector in India valued at approximately $ 10 billion in 2015 at end consumer prices and is growing at 10-12 percent annually. Currently, the Indian medical devices industry represents just over 2 p...
Registration of Drug Product dossier application as per EU Guidelines
Due to variations in the regulatory norms of registration dossier in different countries, there is a strong need for harmonization by ICH for approval of drugs. Generic drugs in EU are approved under the Marketing Author...
COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.
To waive a complete and systemic Bioequivalence (BE) study, Biowaiver or Request for a Biowaiver is a fast track approach to boost the drug development process. Over the past three-four years the Biowaiver market shows g...
UNDERSTANDING TECHNICAL BARRIERS TO TRADE AGREEMENT
Signing of formation of World Trade Organization has transformed trade, services and intellectual property into a mutual, predictable exchange of trade and intellectual property protection among member countries. Countri...